BRAF Inhibition in BRAF^V600-Mutant Gliomas: Results From the VE-BASKET Study.

ABSTRACT:

Purpose

BRAF^V600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAF^V600, in patients with gliomas that harbor this mutation.

Patients and methods

The VE-BASKET study was an open-label, nonrandomized, multicohort study for BRAF^V600-mutant nonmelanoma cancers. Patients with BRAF^V600-mutant glioma received vemurafenib 960 mg twice per day continuously until disease progression, withdrawal, or intolerable adverse effects. Key end points included confirmed objective response rate by RECIST version 1.1, progression-free

SUBMITTER: Kaley T 

PROVIDER: S-EPMC6286161 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature